We are live on ! Find out more
ADCT icon

ADC Therapeutics
ADCT

51 hedge funds and large institutions have $1.01B invested in ADC Therapeutics in 2020 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

10% more capital invested

Capital invested by funds: $921M → $1.01B (+$90.8M)

4.4% more ownership

Funds ownership: 36.79% → 41.19% (+4.4%)

7% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 15

2% less funds holding

Funds holding: 52 → 51 (-1)

63% less call options, than puts

Call options by funds: $227K | Put options by funds: $611K

Holders
51
Holders Change
-1
Holders Change %
-1.92%
% of All Funds
0.9%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
14
Increased
16
Reduced
13
Closed
15
Calls
$227K
Puts
$611K
Net Calls
-$384K
Net Calls Change
-$51K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$40.9M
2
JP Morgan Chase
JP Morgan Chase
New York
+$29.4M
3
AllianceBernstein
AllianceBernstein
Tennessee
+$16.5M
4
EAM
Eventide Asset Management
Massachusetts
+$16.2M
5
RG
Redmile Group
California
+$13.3M

Top Sellers

Rank Fund Capital Flow
1
MF
Magnetar Financial
Illinois
-$49.6M
2
DM
Deerfield Management
New York
-$9.9M
3
BBA
Baker Bros. Advisors
New York
-$8.83M
4
PI
PEAK6 Investments
Illinois
-$6.59M
5
IM
Islet Management
New York
-$6.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
51
Deerfield Management
New York
– -$9.9M -300,000 Closed
IM
52
Islet Management
New York
– -$6.2M -188,000 Closed
PCM
53
Pinz Capital Management
New York
– -$4.11M -124,601 Closed
ECM
54
Element Capital Management
New York
– -$3.57M -108,138 Closed
MIM
55
Monashee Investment Management
Massachusetts
– -$3.3M -100,000 Closed
ECM
56
ExodusPoint Capital Management
New York
– -$2.69M -81,624 Closed
UBS AM
57
UBS AM
Illinois
– -$2.62M -79,563 Closed
LCM
58
Laurion Capital Management
New York
– -$1.81M -55,000 Closed
Tudor Investment Corp
59
Tudor Investment Corp
Connecticut
– -$1.65M -50,000 Closed
CCM
60
CAAS Capital Management
New York
– -$1.16M -35,000 Closed
D.E. Shaw & Co
61
D.E. Shaw & Co
New York
– -$914K -27,713 Closed
FAM
62
Fred Alger Management
New York
– -$906K -27,457 Closed
ECM
63
Endurant Capital Management
California
– -$396K -12,000 Closed
FCA
64
FinTrust Capital Advisors
South Carolina
– -$6 -180 Closed
Royal Bank of Canada
65
Royal Bank of Canada
Ontario, Canada
– -$1K -22 Closed
CS
66
Candriam SCA
Luxembourg
– +$295 +9 New
1 2
3

ADCT Hedge Fund Activity: Q4 2020 in Review

51 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q4 2020, worth a combined $1.01B — up 9.9% from $921M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ADCT and 14 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 16 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $40.9M. The largest seller was Magnetar Financial, cutting an estimated $49.6M.

  • 51 institutional investors held ADC Therapeutics (ADCT) as of Q4 2020, down from 52 in Q3 2020.
  • Funds reported $1.01B of ADC Therapeutics stock for Q4 2020, up 9.9% quarter-over-quarter.
  • 14 funds opened new ADC Therapeutics positions in Q4 2020 and 15 closed out, a net change of -1 holder.
  • The largest ADC Therapeutics buyer in Q4 2020 was T. Rowe Price Associates, an estimated $40.9M added.
  • The largest ADC Therapeutics seller in Q4 2020 was Magnetar Financial, an estimated $49.6M sold.

Based on aggregated 13F filings for Q4 2020.